Diabetes Australia supporting research into cardiovascular health 8 October 2019 A new class of diabetes drugs – SGLT 2 inhibitors could have a range of benefits for cardiovascular health. With the support of a grant from the Diabetes Australia Research Trust Associate Professor Neale Cohen, from the Baker Heart and Diabetes Institute, is trying to find new therapies to improve the health of people with diabetes. SGLT2 inhibitors work by helping the kidneys lower blood glucose levels. “Recent studies into SGLT2 inhibitors have found benefits to heart health, however at this stage we don’t really understand how those benefits work,” Associate Professor Cohen said. “We want to understand how these drugs help the heart, and if they might have benefits for the heart over and above their ability to lower blood glucose levels.”
Blog 4 December 2023 Are you up to date with your COVID-19 vaccination? As we head into the festive season it's a good time to make sure you are up-to-date with your COVID-19 vaccination. Continue Reading
Media releases 22 November 2023 Regional and remote Australians urged to get late flu vaccine People living with diabetes in rural and remote areas are being urged to get their flu shot now after low rates of flu vaccinations have put communities at risk across Australia this year. Continue Reading
News 17 August 2023 Update on Fiasp insulin Diabetes Australia have been consistently talking with both the Federal Government and Novo Nordisk about the need for a solution before 1 October 2023. Continue Reading